Stockscreener 앱 받기
1.37
7.03%
0.09
Lexicon Pharmaceuticals Inc 주식(LXRX)의 최신 뉴스
Lexicon Pharmaceuticals (NASDAQ:LXRX) delivers shareholders notable 99% return over 1 year, surging 17% in the last week alone - simplywall.st
Lexicon flags $10 mln Novo Nordisk milestone and 2026 NDA plans - MSN
Aug PreEarnings: Will Lexicon Pharmaceuticals Inc. stock deliver long term returnsQuarterly Market Summary & Expert Approved Momentum Trade Ideas - Bộ Nội Vụ
Published on: 2026-01-13 21:48:56 - Bộ Nội Vụ
Lexicon Pharmaceuticals Publishes Relief is Possible, Ensuring Access to Effective Treatments for Chronic Pain - marketscreener.com
Lexicon Pharmaceuticals provides a business and pipeline update at the 44th annual J.P. Morgan healthcare conference - marketscreener.com
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Experimental heart, diabetes and pain drugs move ahead at Lexicon - Stock Titan
Published on: 2026-01-10 20:09:17 - ulpravda.ru
Lexicon Pharmaceuticals Releases White Paper on Addressing Chronic Pain with Non-Opioid Treatments Following Stakeholder Roundtable - Quiver Quantitative
MarketsMedicine Hat News - FinancialContent
Will Lexicon Pharmaceuticals Inc. stock maintain growth storyAnalyst Downgrade & Fast Gain Stock Tips - Улправда
Making Medical Innovation Matter To Patients With Simplified Trial Design - Clinical Leader
Is Lexicon Pharmaceuticals Inc. stock cheap at current valuationTrade Performance Summary & Growth-Oriented Investment Plans - Улправда
Market Rankings: Can Lexicon Pharmaceuticals Inc. stock continue upward trendMarket Performance Recap & Scalable Portfolio Growth Ideas - ulpravda.ru
Is Lexicon Pharmaceuticals Inc. stock resilient to inflationJuly 2025 PostEarnings & Real-Time Buy Signal Notifications - Улправда
Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Lexicon Pharmaceuticals Inc Stock Analysis and ForecastInstitutional Buying Trends & Calculate Profit Targets With AI Accuracy - earlytimes.in
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Aug Update: Will Lexicon Pharmaceuticals Inc stock outperform Dow Jones index2025 Big Picture & Low Drawdown Trading Strategies - moha.gov.vn
Lexicon Pharmaceuticals (NASDAQ:LXRX) Is Using Debt Safely - 富途牛牛
Profit Recap: Can Lexicon Pharmaceuticals Inc stock continue upward trendRisk Management & Free Daily Entry Point Trade Alerts - moha.gov.vn
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Cross Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) stock most popular amongst private equity firms who own 48%, while individual investors hold 27% - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Lexicon Pharmaceuticals (LXRX) and Pfizer (PFE) - The Globe and Mail
Lexicon Pharmaceuticals accelerates partnerships with patients on innovative therapies - Traders Union
How currency fluctuations impact Lexicon Pharmaceuticals Inc. stockWeekly Profit Summary & Stock Portfolio Risk Control - Улправда
Patterns Watch: Will Lexicon Pharmaceuticals Inc. stock outperform Dow Jones index2025 Fundamental Recap & Smart Allocation Stock Reports - moha.gov.vn
Investment Report: Why Lexicon Pharmaceuticals Inc. stock appeals to dividend seekers2025 Buyback Activity & Risk Managed Trade Strategies - Улправда
Lexicon Pharmaceuticals Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
AI Stocks: Can Lexicon Pharmaceuticals Inc. stock beat market expectations this quarterVolume Spike & Real-Time Stock Movement Alerts - Улправда
Why Lexicon Pharmaceuticals Inc. stock is a must watch in 2025July 2025 Patterns & Entry Point Strategy Guides - DonanımHaber
Can Lexicon Pharmaceuticals Inc. stock weather global recessionMarket Sentiment Report & Comprehensive Market Scan Reports - DonanımHaber
Can Lexicon Pharmaceuticals Inc. stock rebound after recent weaknessWeekly Profit Recap & Free Fast Entry Momentum Trade Alerts - DonanımHaber
How Lexicon Pharmaceuticals Inc. stock benefits from tech adoptionJuly 2025 Final Week & AI Optimized Trade Strategies - DonanımHaber
Surprises Report: Will Lexicon Pharmaceuticals Inc. stock deliver long term returnsEarnings Growth Report & Daily Oversold Stock Bounce Ideas - Улправда
Is Lexicon Pharmaceuticals Inc. stock in correction or buying zone2025 Key Highlights & Real-Time Price Movement Reports - Улправда
Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) dropped from NASDAQ Biotechnology Index - marketscreener.com
Can Lexicon Pharmaceuticals Inc. stock continue upward trendMarket Trend Summary & Capital Efficient Trade Techniques - Улправда
Why Lexicon Pharmaceuticals Inc. stock appeals to dividend seekersJuly 2025 Big Picture & Detailed Earnings Play Strategies - Улправда
Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money - simplywall.st
Short Covering: How risky is Lexicon Pharmaceuticals Inc stock now2025 Fundamental Recap & Community Verified Trade Alerts - moha.gov.vn
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Cross Above 200 Day Moving AverageTime to Sell? - MarketBeat
Lexicon Pharmaceuticals to advance obesity treatment with new ACSL5 inhibitor data - Traders Union
Novo Nordisk (NVO) Collaborates with Lexicon on Obesity Treatmen - GuruFocus
Lexicon Pharmaceuticals Publishes Preclinical Data Supporting ACSL5 as Target for Obesity Treatment - Quiver Quantitative
Lexicon publishes preclinical data supporting LX9851 obesity treatment - StreetInsider
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851 - Yahoo Finance
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Clinical data on effect of sotagliflozin on adipose distribution in non-diabetic patients - marketscreener.com
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum - The Manila Times
Clinical Data On Effect Of Sotagliflozin On Adipose Distribution In Non-Diabetic Patients - TradingView
Lexicon Pharmaceuticals to Present Clinical Data on Sotagliflozin at CVCT 2025 Conference - Quiver Quantitative
4.73%
0.92%
자본화:
|
볼륨(24시간):